The reasons were structural: Supply was fragmented across thousands of small private practices, billing was opaque, and most patients were unaware the benefit even existed
These materials are not for human or animal consumption , medical treatment, or diagnostic procedures of any kind
PMID: 39602114
Patients who develop symptoms of pancreatitis (e.g., upper abdominal pain radiating to the back, nausea, vomiting) should be evaluated promptly, and tirzepatide should be discontinued if pancreatitis is confirmed
But unfortunately, because of the opacity of the way, contracting is done on the pharmacy benefit side, were never going to know what those numbers are, and were never going to know how much of it is captured as profit by the PBMs, and how much of it may at some point be passed back on to the employers or to the government as premium support
the effects of AICAR on the intracellular lipid deposition were reversed by PARP-1 (Figure 4D)